<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="251">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02217878</url>
  </required_header>
  <id_info>
    <org_study_id>CMUMK202</org_study_id>
    <nct_id>NCT02217878</nct_id>
  </id_info>
  <brief_title>Influence of Morphine on Pharmacokinetics and Pharmacodynamics of Ticagrelor in Patients With Acute Myocardial Infarction</brief_title>
  <acronym>IMPRESSION</acronym>
  <official_title>A Randomized, Double-blind Study Evaluating the Influence of Morphine on Pharmacokinetics and Pharmacodynamics of Ticagrelor and Its Active Metabolite (AR-C124910XX) in Patients With ST-segment Elevation Myocardial Infarction and Non-ST-segment Elevation Myocardial Infarction.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Collegium Medicum w Bydgoszczy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Collegium Medicum w Bydgoszczy</source>
  <oversight_info>
    <authority>Poland: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the IMPRESSION study is to determine whether intravenous administration of
      morphine prior to ticagrelor administration in ST-segment elevation myocardial infarction
      (STEMI) patients and in non-ST-segment elevation myocardial infarction (NSTEMI) patients
      alters the plasma concentrations of ticagrelor and its active metabolite and whether it is
      associated with any negative impact on the antiplatelet effect of ticagrelor.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The European Society of Cardiology and American Heart Association guidelines recommend use
      of morphine as a treatment of choice for pain relief in STEMI patients. However, this
      recommendation, although strong, is only based on expert consensus (class of recommendation
      I, level of evidence C). Morphine, apart from its analgesic effects, also alleviates the
      work of breathing and reduces anxiety. On the other hand, despite its favorable analgesic
      and sedative actions, morphine also exerts adverse effects, which include hypotension,
      bradycardia, respiratory depression, vomiting and reduction of gastrointestinal motility.
      Some of the previously listed morphine's side effects could affect the intestinal absorption
      and thus pharmacokinetics and pharmacodynamics of orally administered drugs which are
      concomitantly used with morphine. At present, no pharmacokinetic and pharmacodynamic data
      regarding the concurrent use of morphine and P2Y12 blockers in the STEMI or NSTEMI setting
      are available. Therefore, evidence-based verification of morphine's influence on
      pharmacokinetics and pharmacodynamics of ticagrelor and its active metabolite (AR-C124910XX)
      could provide a valuable insight in the knowledge regarding modern acute myocardial
      infarction management.

      Predefined subanalysis: aimed to investigate which one of platelet reactivity assessment
      methods utilized in the study (VASP assay, MEA, LTA, VerifyNow) best reflects concentration
      of ticagrelor and its active metabolite (AR-C124910XX).

      Since there is no reference study examining pharmacokinetics of ticagrelor in STEMI or
      NSTEMI patients, we decided to perform an internal pilot study of approximately 30 patients
      (15 patients for each arm) for estimating the final sample size.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve for Ticagrelor (AUC 0-12h)</measure>
    <time_frame>prior to the initial dose and 30min, 1h, 2h, 3h, 4h, 6h, 12h post dose</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve for AR-C124910XX (AUC 0-12h)</measure>
    <time_frame>prior to the initial dose and 30min, 1h, 2h, 3h, 4h, 6h, 12h post dose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Concentration (Cmax) of Ticagrelor and AR-C124910XX</measure>
    <time_frame>12 hours</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Concentration (Cmax) for Ticagrelor and AR-C124910XX</measure>
    <time_frame>12 hours</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet Reactivity Index (PRI) Assessed by VASP Assay</measure>
    <time_frame>prior to the initial dose and 30min, 1h, 2h, 3h, 4h, 6h, 12h post dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>It will be assessed in all study participants in all predefined time points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet Arbitrary Aggregation Units/Min Assessed by Multiple Electrode Aggregometry</measure>
    <time_frame>prior to the initial dose and 30min, 1h, 2h, 3h, 4h, 6h, 12h post dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>It will be assessed in all predefined time points in all study participants except those treated with GP IIb/IIIa receptor inhibitors.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>P2Y12 Reaction Units (PRU) Assessed by VerifyNow</measure>
    <time_frame>prior to the initial dose and 30min, 1h, 2h, 3h, 4h, 6h, 12h post dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>It will be assessed in at least 30% of study participants (with 1:1 ratio between morphine and placebo arms) in all predefined time points. Measurements will not be performed in patients treated with GP IIb/IIIa receptor inhibitors.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve for Ticagrelor (AUC 0-6h)</measure>
    <time_frame>prior to the initial dose and 30min, 1h, 2h, 3h, 4h, 6h post dose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve for AR-C124910XX (AUC 0-6)</measure>
    <time_frame>prior to the initial dose and 30min, 1h, 2h, 3h, 4h, 6h post dose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With High Platelet Reactivity (HPR) After the Loading Dose of Ticagrelor Assessed With VASP, MEA and VerifyNow</measure>
    <time_frame>2 hours</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Platelet Reactivity Below the Cut-off Value for High Platelet Reactivity (HPR) Evaluated With VASP, MEA and VerifyNow</measure>
    <time_frame>12 hours</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">74</enrollment>
  <condition>ST-segment Elevation Myocardial Infarction</condition>
  <condition>Non-ST-segment Elevation Myocardial Infarction</condition>
  <condition>VA Drug Interactions [VA Drug Interaction]</condition>
  <arm_group>
    <arm_group_label>Morphine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>morphine sulfate 5 mg IV followed by 180 mg loading dose of ticagrelor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>sodium chloride 0,9% 5 mg IV followed by 180 mg loading dose of ticagrelor</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Morphine</intervention_name>
    <description>IV bolus injection</description>
    <arm_group_label>Morphine</arm_group_label>
    <other_name>Morphine sulfate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>IV bolus injection</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Sodium chloride 0,9%</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor</intervention_name>
    <description>180 mg loading dose</description>
    <arm_group_label>Morphine</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Brilique</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  provision of informed consent prior to any study specific procedures

          -  diagnosis of acute ST-segment elevation myocardial infarction or acute non-ST-segment
             elevation myocardial infarction

          -  male or non-pregnant female, aged 18-80 years old

          -  provision of informed consent for angiography and PCI

        Exclusion Criteria:

          -  chest pain described by the patient as unbearable or patient's request for analgesics

          -  prior morphine administration during the current STEMI or NSTEMI

          -  treatment with ticlopidine, clopidogrel, prasugrel or ticagrelor within 14 days
             before the study enrollment

          -  hypersensitivity to ticagrelor

          -  current treatment with oral anticoagulant or chronic therapy with
             low-molecular-weight heparin

          -  active bleeding

          -  history of intracranial hemorrhage

          -  recent gastrointestinal bleeding (within 30 days)

          -  history of coagulation disorders

          -  platelet count less than &lt;100 x10^3/mcl

          -  hemoglobin concentration less than 10.0 g/dl

          -  history of moderate or severe hepatic impairment

          -  history of major surgery or severe trauma (within 3 months)

          -  patients considered by the investigator to be at risk of bradycardic events

          -  second or third degree atrioventricular block during screening for eligibility

          -  history of asthma or severe chronic obstructive pulmonary disease

          -  patient required dialysis

          -  manifest infection or inflammatory state

          -  Killip class III or IV during screening for eligibility

          -  respiratory failure

          -  history of severe chronic heart failure (NYHA class III or IV)

          -  concomitant therapy with strong CYP3A inhibitors (ketoconazole, itraconazole,
             voriconazole, telithromycin, clarithromycin, nefazadone, ritonavir, saquinavir,
             nelfinavir, indinavir, atazanavir) or strong CYP3A inducers (rifampicin, phenytoin,
             carbamazepine, dexamethasone, phenobarbital) within 14 days and during study
             treatment

          -  body weight below 50 kg
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prof. Jacek Kubica, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Collegium Medicum im. Ludwika Rydygiera w Bydgoszczy, Uniwersytet Miko≈Çaja Kopernika w Toruniu</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cardiology Department, Dr. A. Jurasz University Hospital</name>
      <address>
        <city>Bydgoszcz</city>
        <state>Kujawsko-pomorskie</state>
        <zip>85-094</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <lastchanged_date>February 4, 2016</lastchanged_date>
  <firstreceived_date>August 14, 2014</firstreceived_date>
  <firstreceived_results_date>February 4, 2016</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Collegium Medicum w Bydgoszczy</investigator_affiliation>
    <investigator_full_name>Jacek Kubica</investigator_full_name>
    <investigator_title>Prof. dr hab.</investigator_title>
  </responsible_party>
  <keyword>ST-segment elevation myocardial infarction</keyword>
  <keyword>non-ST-segment elevation myocardial infarction</keyword>
  <keyword>ticagrelor</keyword>
  <keyword>morphine</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>pharmacodynamics</keyword>
  <keyword>drug interactions</keyword>
  <keyword>VASP assay</keyword>
  <keyword>Multiple Electrode Aggregometry</keyword>
  <keyword>VerifyNow</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Morphine</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Morphine</title>
          <description>morphine sulfate 5 mg IV followed by 180 mg loading dose of ticagrelor
Morphine: IV bolus injection
Ticagrelor: 180 mg loading dose</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>sodium chloride 0,9% 5 mg IV followed by 180 mg loading dose of ticagrelor
Placebo: IV bolus injection
Ticagrelor: 180 mg loading dose</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="37"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>required morphine due to chest pain</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>initial diagnosis of STEMI not confirmed</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Morphine</title>
          <description>morphine sulfate 5 mg IV followed by 180 mg loading dose of ticagrelor
Morphine: IV bolus injection
Ticagrelor: 180 mg loading dose</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>sodium chloride 0,9% 5 mg IV followed by 180 mg loading dose of ticagrelor
Placebo: IV bolus injection
Ticagrelor: 180 mg loading dose</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="35"/>
                <measurement group_id="B2" value="35"/>
                <measurement group_id="B3" value="70"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="60.7" spread="10.5"/>
                <measurement group_id="B2" value="62.5" spread="10.5"/>
                <measurement group_id="B3" value="61.5" spread="10.3"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="12"/>
                <measurement group_id="B2" value="7"/>
                <measurement group_id="B3" value="19"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="23"/>
                <measurement group_id="B2" value="28"/>
                <measurement group_id="B3" value="51"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="27.6" spread="4.3"/>
                <measurement group_id="B2" value="27.4" spread="4.0"/>
                <measurement group_id="B3" value="27.5" spread="4.2"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>STEMI</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="24"/>
                <measurement group_id="B2" value="21"/>
                <measurement group_id="B3" value="45"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>GP IIb/IIIa administration</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="10"/>
                <measurement group_id="B2" value="6"/>
                <measurement group_id="B3" value="16"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Hypertension</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="15"/>
                <measurement group_id="B2" value="21"/>
                <measurement group_id="B3" value="36"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Diabetes mellitus</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="8"/>
                <measurement group_id="B2" value="5"/>
                <measurement group_id="B3" value="13"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Dyslipidaemia</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="30"/>
                <measurement group_id="B2" value="31"/>
                <measurement group_id="B3" value="61"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Current smoker</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="17"/>
                <measurement group_id="B2" value="14"/>
                <measurement group_id="B3" value="31"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Prior AMI</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="5"/>
                <measurement group_id="B2" value="8"/>
                <measurement group_id="B3" value="13"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Prior PCI</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="4"/>
                <measurement group_id="B2" value="9"/>
                <measurement group_id="B3" value="13"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Prior CABG</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Prior non-severe heart failure</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="3"/>
                <measurement group_id="B3" value="3"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Prior non-haemorrhagic stroke</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="1"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Peripheral arterial disease</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="3"/>
                <measurement group_id="B2" value="1"/>
                <measurement group_id="B3" value="4"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Chronic renal disease</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
                <measurement group_id="B2" value="2"/>
                <measurement group_id="B3" value="3"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Chronic obstructive pulmonary disease</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="2"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gout</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
                <measurement group_id="B2" value="2"/>
                <measurement group_id="B3" value="3"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Concentration-time Curve for Ticagrelor (AUC 0-12h)</title>
        <time_frame>prior to the initial dose and 30min, 1h, 2h, 3h, 4h, 6h, 12h post dose</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Morphine</title>
            <description>morphine sulfate 5 mg IV followed by 180 mg loading dose of ticagrelor
Morphine: IV bolus injection
Ticagrelor: 180 mg loading dose</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>sodium chloride 0,9% 5 mg IV followed by 180 mg loading dose of ticagrelor
Placebo: IV bolus injection
Ticagrelor: 180 mg loading dose</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="35"/>
                  <measurement group_id="O2" value="35"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Area Under the Plasma Concentration-time Curve for Ticagrelor (AUC 0-12h)</title>
            <units>ng*h/mL</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="6307" spread="4359"/>
                  <measurement group_id="O2" value="9791" spread="5136"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Concentration-time Curve for AR-C124910XX (AUC 0-12h)</title>
        <time_frame>prior to the initial dose and 30min, 1h, 2h, 3h, 4h, 6h, 12h post dose</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Concentration (Cmax) of Ticagrelor and AR-C124910XX</title>
        <time_frame>12 hours</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Maximum Concentration (Cmax) for Ticagrelor and AR-C124910XX</title>
        <time_frame>12 hours</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Platelet Reactivity Index (PRI) Assessed by VASP Assay</title>
        <description>It will be assessed in all study participants in all predefined time points.</description>
        <time_frame>prior to the initial dose and 30min, 1h, 2h, 3h, 4h, 6h, 12h post dose</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Platelet Arbitrary Aggregation Units/Min Assessed by Multiple Electrode Aggregometry</title>
        <description>It will be assessed in all predefined time points in all study participants except those treated with GP IIb/IIIa receptor inhibitors.</description>
        <time_frame>prior to the initial dose and 30min, 1h, 2h, 3h, 4h, 6h, 12h post dose</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>P2Y12 Reaction Units (PRU) Assessed by VerifyNow</title>
        <description>It will be assessed in at least 30% of study participants (with 1:1 ratio between morphine and placebo arms) in all predefined time points. Measurements will not be performed in patients treated with GP IIb/IIIa receptor inhibitors.</description>
        <time_frame>prior to the initial dose and 30min, 1h, 2h, 3h, 4h, 6h, 12h post dose</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Concentration-time Curve for Ticagrelor (AUC 0-6h)</title>
        <time_frame>prior to the initial dose and 30min, 1h, 2h, 3h, 4h, 6h post dose</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Concentration-time Curve for AR-C124910XX (AUC 0-6)</title>
        <time_frame>prior to the initial dose and 30min, 1h, 2h, 3h, 4h, 6h post dose</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With High Platelet Reactivity (HPR) After the Loading Dose of Ticagrelor Assessed With VASP, MEA and VerifyNow</title>
        <time_frame>2 hours</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Reach Platelet Reactivity Below the Cut-off Value for High Platelet Reactivity (HPR) Evaluated With VASP, MEA and VerifyNow</title>
        <time_frame>12 hours</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>7 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Morphine</title>
          <description>morphine sulfate 5 mg IV followed by 180 mg loading dose of ticagrelor
Morphine: IV bolus injection
Ticagrelor: 180 mg loading dose</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>sodium chloride 0,9% 5 mg IV followed by 180 mg loading dose of ticagrelor
Placebo: IV bolus injection
Ticagrelor: 180 mg loading dose</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Stent thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Bradyarrhythmic event</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>TIMI minor bleeding</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>TIMI minimal bleeding</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Prof. Jacek Kubica</name_or_title>
      <organization>Collegium Medicum, Nicolaus Copernicus University</organization>
      <phone>+485854023</phone>
      <email>jkubica@cm.umk.pl</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
